July II 2023

During a Targeted Oncology™ Clinical Case Forum™ event, Lyndsay Willmott, MD, discussed the data supporting the use of PARP inhibitors as primary maintenance therapy for patients with ovarian cancer.

In separate live, virtual events, Hussein A. Tawbi, MD, PhD; and Allison Betof Warner, MD, PhD, discuss potential treatment options for a patient with BRAF mutation–negative melanoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ticiana Leal, MD, discussed treatment options for recurrent extensive-stage small cell lung cancer, including topotecan, lurbinectedin, and platinum rechallenge.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel Pollyea, MD, MS, and participants discussed the diagnosis and treatment of a patient with blastic plasmacytoid dendritic cell neoplasm.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tian Zhang, MD, and participants discussed factors that drive their choice of first-line therapy for patients with advanced renal cell carcinoma.

During a Targeted Oncology Case-Based Roundtable event, Cristina Gasparetto, MD, discussed the case of a patient with stage I multiple myeloma and highlighted outcomes of the phase 3 BOSTON trial.

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Coleman, MD, discussed the treatment approach for a patient with relapsed endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark A. Lewis, MD, discussed the results of the SHARP, REFLECT, IMbrave150, and HIMALAYA trials of frontline regimens for patients with hepatocellular carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Doris M. Ponce, MD, and participants discussed treatment goals and management of graft-vs-host disease.

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro Barata, MD, MSc, discussed the CheckMate 9ER, KEYNOTE-426, and CLEAR trials of frontline combination therapies for patients with renal cell carcinoma.

In a comparison of 2 live events from the Targeted Oncology Case-Based Roundtable series, we look at how adding daratumumab to therapy for patients with newly diagnosed disease who cannot receive a transplant has shifted the approach to treatment.

Hatim Husain, MD, discussed with participants the case of a patient with lung adenocarcinoma.

Leo Shunyakov, MD, discussed long-term treatments and trials for patients with newly diagnosed multiple myeloma.

Catherine J. Lee, MD, MS, associate professor of medicine in the Clinical Research Division at Fred Hutchinson Cancer Center in Seattle, Washington, led a live virtual discussion on how to treat patients with chronic graft-vs-host disease (GVHD) and how best to assess the extent of their disease.